Track topics on Twitter Track topics that are important to you
Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based candidate, RGT100, in solid tumors and lymphoma. Rigontec, based in Munich, is exploring RNA’s applications in immuno-oncology. Since the company was founded in 2014, it has raked ...
This awesome article Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Original Article: Immuno-oncology Pioneer Enters the Clinic with its RNA-based TherapyNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...